117 related articles for article (PubMed ID: 2163737)
1. [Vasoactive intestinal peptide receptor in a human pancreatic carcinoma cell line].
Chen Y
Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):135-7, 12. PubMed ID: 2163737
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
3. Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage.
O'Dorisio MS; Shannon BT; Fleshman DJ; Campolito LB
J Immunol; 1989 May; 142(10):3533-6. PubMed ID: 2541199
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition by VIP of the proliferation of pancreatic cancer cells].
Yao CZ
Zhonghua Wai Ke Za Zhi; 1989 Jan; 27(1):42-4, 62. PubMed ID: 2550185
[TBL] [Abstract][Full Text] [Related]
6. Combined ultrastructural and biochemical study of cellular processing of vasoactive intestinal peptide and its receptors in human colonic carcinoma cells in culture.
Hejblum G; Gali P; Boissard C; Astesano A; Marie JC; Anteunis A; Hui Bon Hoa D; Rosselin G
Cancer Res; 1988 Nov; 48(21):6201-10. PubMed ID: 2844402
[TBL] [Abstract][Full Text] [Related]
7. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
8. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the vasoactive intestinal peptide receptor in rat submandibular gland: radioligand binding assay in membrane preparations.
Turner JT; Bylund DB
J Pharmacol Exp Ther; 1987 Sep; 242(3):873-81. PubMed ID: 2821229
[TBL] [Abstract][Full Text] [Related]
10. High-affinity receptors for vasoactive intestinal peptide on human myeloma cells.
Finch RJ; Sreedharan SP; Goetzl EJ
J Immunol; 1989 Mar; 142(6):1977-81. PubMed ID: 2537866
[TBL] [Abstract][Full Text] [Related]
11. Properties of vasoactive intestinal peptide-receptor interaction in rat liver membranes.
Guerrero JM; Prieto JC; Ramírez-Cárdenas R; Calvo JR; Goberna R
Rev Esp Fisiol; 1981 Mar; 37(1):1-8. PubMed ID: 6113623
[TBL] [Abstract][Full Text] [Related]
12. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
13. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
[TBL] [Abstract][Full Text] [Related]
14. Modifications of the binding properties of the human VIP receptor of IGR39 cells by sulfhydryl reagents.
Fouchier F; Forget P; Pic P; Marvaldi J; Pichon J
Eur J Cell Biol; 1992 Dec; 59(2):382-8. PubMed ID: 1337321
[TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2 J.
Svoboda M; De Neef P; Tastenoy M; Christophe J
Eur J Biochem; 1988 Oct; 176(3):707-13. PubMed ID: 2844535
[TBL] [Abstract][Full Text] [Related]
16. Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells.
Broyart JP; Dupont C; Laburthe M; Rosselin G
J Clin Endocrinol Metab; 1981 Apr; 52(4):715-21. PubMed ID: 6259191
[TBL] [Abstract][Full Text] [Related]
17. Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung.
Carstairs JR; Barnes PJ
J Pharmacol Exp Ther; 1986 Oct; 239(1):249-55. PubMed ID: 3020233
[TBL] [Abstract][Full Text] [Related]
18. [Autoradiographic localization and characterization of the ocular binding sites of the VIP (vasoactive intestinal peptide) in albino rats and rabbits].
Denis P; Dussaillant M; Elena PP; Nordmann JP; Rostene W; Laroche L
Ophtalmologie; 1990; 4(1):30-2. PubMed ID: 2174530
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide- and adrenocorticotropin-stimulated adenyl cyclase in cultured adrenal tumor cells: evidence for a specific vasoactive intestinal peptide receptor.
Birnbaum RS; Alfonzo M; Kowal J
Endocrinology; 1980 Apr; 106(4):1270-5. PubMed ID: 6244149
[TBL] [Abstract][Full Text] [Related]
20. Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors.
Xia M; Gaufo GO; Wang Q; Sreedharan SP; Goetzl EJ
J Immunol; 1996 Aug; 157(3):1132-8. PubMed ID: 8757618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
